


Supplemental Figure 1. Phase II study design and summary of expansion cohorts

This analysis focused on patients who had received ≥ 1 second-generation ALK TKI (EXP3B, EXP4, and EXP5; dashed blue box).



ALK, anaplastic lymphoma kinase; CT, chemotherapy; EXP, expansion cohort; *ROS1*, *ROS* proto-oncogene 1; TKI, tyrosine kinase inhibitor.